MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy

eLife

Volumn 2013, Issue 2, 2013, Pages

  Heinrichs, Stefan ^a,b   Conover, Lillian F ^b   Bueso Ramos, Carlos E ^c   Kilpivaara, Outi ^d   Stevenson, Kristen ^b   Neuberg, Donna ^b   Loh, Mignon L ^e   Wu, Wen Shu ^f   Rodig, Scott J ^g   Garcia Manero, Guillermo ^c   Kantarjian, Hagop M ^c   Look, Thomas A ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLASTICIDIN S; CD34 ANTIGEN; CD71 ANTIGEN; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; PUROMYCIN; RED FLUORESCENT PROTEIN; CELL CYCLE PROTEIN; MYBL2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CELL COUNT; BONE MARROW TUMOR; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ERYTHROPOIESIS; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; KARYOTYPING; MICROARRAY ANALYSIS; MOUSE; MYBL2 GENE; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN WEIGHT; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETICS; HAPLOINSUFFICIENCY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER;

CELL CYCLE PROTEINS; DOSAGE COMPENSATION, GENETIC; GENES, TUMOR SUPPRESSOR; HAPLOINSUFFICIENCY; HUMANS; KARYOTYPING; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; TRANS-ACTIVATORS;

EID: 84880612825     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.00825     Document Type: Article

References (33)

1. Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A, et al. 2004. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 64:844-56. doi: 10.1158/0008-5472.CAN-03-2361.
2. Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL, et al. 2010. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 16:59-66. doi: 10.1038/nm.2063.
3. Bejar R, Levine R, Ebert BL. 2011. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 29:504-15. doi: 10.1200/JCO.2010.31.1175.
4. Bench AJ, Nacheva EP, Hood TL, Holden JL, French L, Swanton S, et al. 2000. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 19:3902-13. doi: 10.1038/sj.onc.1203728.
5. Berger AH, Knudson AG, Pandolfi PP. 2011. A continuum model for tumour suppression. Nature 476:163-9. doi: 10.1038/nature10275.
6. Clarke M, Dumon S, Ward C, Jager R, Freeman S, Dawood B, et al. 2012. MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia. Leukemia 27:661-70. doi: 10.1038/leu.2012.241.
7. Del Rey M, O'Hagan K, Dellett M, Aibar S, Colyer HA, Alonso ME, et al. 2012. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes. Leukemia 27:610-8. doi: 10.1038/leu.2012.253.
8. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al. 2008. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451:335-9. doi: 10.1038/nature06494.
9. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. 2007. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385-95. doi: 10.1182/blood-2007-03-082404.
10. Han YC, Park CY, Bhagat G, Zhang J, Wang Y, Fan JB, et al. 2010. microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med 207:475-89. doi: 10.1084/jem.20090831.
11. Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C, et al. 2009. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 23:1605-13. doi: 10.1038/leu.2009.82.
12. Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, et al. 2010. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Genes Chromosomes Cancer 49:390-9. doi: 10.1002/gcc.20748.
13. Knudson AG Jnr. 1971. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-3. doi: 10.1073/pnas.68.4.820.
14. Korenjak M, Taylor-Harding B, Binne UK, Satterlee JS, Stevaux O, Aasland R, et al. 2004. Native E2F/RBF complexes contain Myb-interacting proteins and repress transcription of developmentally controlled E2F target genes. Cell 119:181-93. doi: 10.1016/j.cell.2004.09.034.
15. Lewis PW, Beall EL, Fleischer TC, Georlette D, Link AJ, Botchan MR. 2004. Identification of a Drosophila Myb-E2F2/RBF transcriptional repressor complex. Genes Dev 18:2929-40. doi: 10.1101/gad.1255204.
16. Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N, et al. 2007. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 13:78-83. doi: 10.1038/nm1512.
17. Martinez I, Cazalla D, Almstead LL, Steitz JA, DiMaio D. 2011. miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci USA 108:522-7. doi: 10.1073/pnas.1017346108.
18. Heinrichs et al. eLife 2013;2:e00825. doi: 10.7554/eLife.00825 19 of 20
19. Morrison SJ, Weissman IL. 1994. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1:661-73. doi: 10.1016/1074-7613(94)90037-X.
20. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. 2004. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-26. doi: 10.1056/NEJMoa041588.
21. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, et al. 2010. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 24:756-64. doi: 10.1038/leu.2010.31.
22. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. 2006. GenePattern 2.0. Nat Genet 38:500-1. doi: 10.1038/ng0506-500.
23. Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, et al. 2004. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 36:624-30. doi: 10.1038/ng1361.
24. Shepard JL, Amatruda JF, Stern HM, Subramanian A, Finkelstein D, Ziai J, et al. 2005. A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility. Proc Natl Acad Sci USA 102:13194-9. doi: 10.1073/pnas.0506583102.
25. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. 2012. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 12:599-612. doi: 10.1038/nrc3343.
26. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. 2010. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 16:49-58. doi: 10.1038/nm.2054.
27. Strack RL, Strongin DE, Bhattacharyya D, Tao W, Berman A, Broxmeyer HE, et al. 2008. A noncytotoxic DsRed variant for whole-cell labeling. Nat Methods 5:955-7. doi: 10.1038/nmeth.1264.
28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-50. doi: 10.1073/pnas.0506580102.
29. Tanaka Y, Patestos NP, Maekawa T, Ishii S. 1999. B-myb is required for inner cell mass formation at an early stage of development. J Biol Chem 274:28067-70. doi: 10.1074/jbc.274.40.28067.
30. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, et al. 2002. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13:1977-2000. doi: 10.1091/mbc.02-02-0030.
31. Ye Y, McDevitt MA, Guo M, Zhang W, Galm O, Gore SD, et al. 2009. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res 69:8482-90. doi: 10.1158/0008-5472.CAN-09-1153.
32. Zhu W, Giangrande PH, Nevins JR. 2004. E2Fs link the control of G1/S and G2/M transcription. EMBO J 23:4615-26. doi: 10.1038/sj.emboj.7600459.
33. Heinrichs et al. eLife 2013;2:e00825. doi: 10.7554/eLife.00825 20 of 20